MA31568B1 - Composes d'imidazothiazole modulant les sirtuines - Google Patents

Composes d'imidazothiazole modulant les sirtuines

Info

Publication number
MA31568B1
MA31568B1 MA32518A MA32518A MA31568B1 MA 31568 B1 MA31568 B1 MA 31568B1 MA 32518 A MA32518 A MA 32518A MA 32518 A MA32518 A MA 32518A MA 31568 B1 MA31568 B1 MA 31568B1
Authority
MA
Morocco
Prior art keywords
diseases
disorders
modulating
sirtuins
sirtuin
Prior art date
Application number
MA32518A
Other languages
English (en)
Inventor
Jean Bemis
Jeremy S Disch
Michael Jirousek
Walter Joseph Lunsmann
Pui Yee Ng
Chi B Vu
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31568(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of MA31568B1 publication Critical patent/MA31568B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS MODULANT LES SIRTUINES ET LEURS MÉTHODES D'UTILISATION. CES COMPOSÉS MODULANT LES SIRTUINES PEUVENT ÊTRE UTILISÉS POUR PROLONGER LA DURÉE DE VIE D'UNE CELLULE ET POUR TRAITER ET/OU PRÉVENIR UN GRAND NOMBRE DE MALADIES ET DE TROUBLES, Y COMPRIS, PAR EXEMPLE, DES MALADIES ET DES TROUBLES LIÉS AU VIEILLISSEMENT ET AU STRESS, LE DIABÈTE, L'OBÉSITÉ, DES MALADIES NEURODÉGÉNÉRATIVES, UNE MALADIE CARDIOVASCULAIRE, DES TROUBLES DE LA COAGULATION SANGUINE, L'INFLAMMATION, LE CANCER, ET/OU LES BOUFFÉES VASOMOTRICES, AINSI QUE DES MALADIES OU DES TROUBLES POUVANT BÉNÉFICIER D'UNE ACTIVITÉ MITOCHONDRIALE PLUS INTENSE. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS COMPRENANT UN COMPOSÉ MODULANT LES SIRTUINES, COMBINÉ À UN AUTRE AGENT THÉRAPEUTIQUE.
MA32518A 2007-06-20 2010-01-15 Composes d'imidazothiazole modulant les sirtuines MA31568B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663307P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
MA31568B1 true MA31568B1 (fr) 2010-08-02

Family

ID=39810276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32518A MA31568B1 (fr) 2007-06-20 2010-01-15 Composes d'imidazothiazole modulant les sirtuines

Country Status (26)

Country Link
US (2) US7829556B2 (fr)
EP (1) EP2167510B1 (fr)
JP (1) JP5281081B2 (fr)
KR (1) KR101525268B1 (fr)
CN (1) CN101874031B (fr)
AR (1) AR067106A1 (fr)
AU (1) AU2008266746B2 (fr)
BR (1) BRPI0813653A2 (fr)
CA (1) CA2692099C (fr)
CL (1) CL2008001821A1 (fr)
CO (1) CO6261382A2 (fr)
CR (1) CR11231A (fr)
DO (1) DOP2009000283A (fr)
EA (1) EA018182B1 (fr)
ES (1) ES2534544T3 (fr)
IL (1) IL202729A (fr)
MA (1) MA31568B1 (fr)
MX (1) MX2009013976A (fr)
MY (1) MY149316A (fr)
NZ (1) NZ581989A (fr)
PE (1) PE20090423A1 (fr)
TW (1) TW200918542A (fr)
UA (1) UA104127C2 (fr)
UY (1) UY31170A1 (fr)
WO (1) WO2008156866A1 (fr)
ZA (1) ZA200908882B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2006094236A1 (fr) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine
US20070037865A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2009099643A1 (fr) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Utilisation d'activateurs ou d'inhibiteurs de sirt1 pour moduler une réponse immunitaire
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US8685970B2 (en) * 2008-05-01 2014-04-01 GlaxoSmithKline, LLC Quinolines and related analogs as sirtuin modulators
WO2010003048A1 (fr) 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles et analogues associés en tant que modulateurs de sirtuine
WO2010037127A1 (fr) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals, Inc. Analogues de chroménone en tant que modulateurs de sirtuine
WO2010059617A2 (fr) 2008-11-18 2010-05-27 Setpoint Medical Corporation Dispositifs et procédés permettant d'optimiser la pose d'une électrode pour stimulation anti-inflammatoire
JP2012511048A (ja) 2008-12-08 2012-05-17 ノースウェスタン ユニバーシティ Ｈｓｆ−１の改変方法
MX2011006555A (es) 2008-12-19 2011-08-03 Sirtris Pharmaceuticals Inc Compuestos de tiazolopiridina moduladores de sirtuina.
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
WO2010144578A2 (fr) 2009-06-09 2010-12-16 Setpoint Medical Corporation Manchon pour nerf muni d'une poche pour stimulateur sans fil
CA2779303A1 (fr) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Pyridines bicycliques et analogues en tant que modulateurs de la sirtuine
BR112012010587A2 (pt) 2009-11-06 2015-09-29 David Gladstone Inst métodos e composições para modulação de níveis de tau.
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) * 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (fr) 2009-12-23 2019-09-18 Setpoint Medical Corporation Dispositifs de stimulation neurale et systèmes pour le traitement d'une inflammation chronique
EP2993236A1 (fr) 2010-04-15 2016-03-09 Glaxosmithkline LLC Activateurs de sirtuine et dosages d'activation
JP2013525483A (ja) * 2010-05-03 2013-06-20 カッパーアールエヌエー，インコーポレイテッド サーチュイン（ｓｉｒｔ）に対する天然アンチセンス転写物の阻害によるサーチュイン（ｓｉｒｔ）関連疾患の治療
US20130171125A1 (en) * 2010-05-11 2013-07-04 National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DDS), U.S. Government Methods for the Regulation of Cellular Metabolism Through the Modulation of SIRT3 Activity
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CA2841748C (fr) 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions et procedes de modulation de voies metaboliques
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013158664A2 (fr) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Utilisation de virus modifiés pour tuer spécifiquement les cellules sénescentes
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
CA2902879C (fr) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine et acide nicotinique reduisant les taux de lipides
WO2015002892A1 (fr) * 2013-07-01 2015-01-08 Meier Joshua Abraham Méthodes de traitement de maladies impliquant de moduler les délétions d'adn mitochondrial
US9724319B2 (en) 2014-02-27 2017-08-08 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
KR101839688B1 (ko) 2015-08-21 2018-03-19 중앙대학교 산학협력단 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017123161A1 (fr) * 2016-01-15 2017-07-20 Agency For Science, Technology And Research Inhibition de la croissance intracellulaire d'espèces de mycobactéries et ses applications
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127758A1 (fr) 2016-01-20 2017-07-27 Setpoint Medical Corporation Microstimulateurs implantables et systèmes de recharge par induction
EP3405107B1 (fr) 2016-01-20 2023-04-12 Setpoint Medical Corporation Commande de stimulation vagale
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017147180A1 (fr) 2016-02-22 2017-08-31 The Trustees Of The University Of Pennsylvania Procédés pour améliorer la régénération du foie
WO2019036470A1 (fr) 2017-08-14 2019-02-21 Setpoint Medical Corporation Test de dépistage pour stimulation du nerf vague
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN109700790A (zh) * 2018-12-28 2019-05-03 中南大学湘雅医院 一种靶向AQP3的抗皮肤衰老药物Butein
CN111000854B (zh) * 2019-12-30 2023-06-09 昆药集团股份有限公司 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for stimulating the vagus nerve
WO2023244862A1 (fr) * 2022-06-17 2023-12-21 Codagen Biosciences, Inc. Composés de modulation des sirtuines, comprenant des composés d'activation des sirtuines, et leurs applications
US12012370B1 (en) 2022-12-29 2024-06-18 Codagen Biosciences, Inc. Sirtuin modulating compounds and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
US3517007A (en) * 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
ZA735753B (en) 1972-09-14 1974-07-31 American Cyanamid Co Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles
US4018932A (en) * 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
JPH0576084A (ja) 1991-09-11 1993-03-26 Matsushita Electric Ind Co Ltd 遠隔表示装置
JPH05289689A (ja) 1992-04-06 1993-11-05 Sanyo Electric Co Ltd 可搬性規則音声合成装置
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
WO2003000682A1 (fr) * 2001-06-25 2003-01-03 Merck & Co., Inc. Composes d'heteroaryle fondus (pyrimidyle)(phenyle) substitues inhibiteurs de p38 et de la kinase pkg
WO2003007959A1 (fr) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
CA2455100C (fr) 2001-07-27 2013-05-28 Curis, Inc. Mediateurs des voies de signalisation hedgehog, compositions associees et utilisations de ces dernieres
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005298333A (ja) 2001-11-15 2005-10-27 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
MXPA05009245A (es) * 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
JP2006519791A (ja) 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
ZA200605248B (en) 2003-12-15 2007-10-31 Japan Tobacco Inc Cyclopropane compounds and pharmaceutical use thereof
WO2005069998A2 (fr) 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Noveaux composes activant sirtuine et leurs methodes de preparation
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
PT1755391E (pt) * 2004-06-04 2016-02-03 Univ Washington Métodos e composições para o tratamento de neuropatias
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006094236A1 (fr) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Dérivés de n-phénylbenzamide en tant qu'agents régulant la sirtuine
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
US20070037865A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
AU2008325148A1 (en) 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
MX2009013976A (es) 2010-04-27
ES2534544T3 (es) 2015-04-24
BRPI0813653A2 (pt) 2014-12-30
CN101874031B (zh) 2013-02-20
US20110015192A1 (en) 2011-01-20
EA018182B1 (ru) 2013-06-28
EP2167510A1 (fr) 2010-03-31
EA201070034A1 (ru) 2010-06-30
AR067106A1 (es) 2009-09-30
DOP2009000283A (es) 2011-03-31
UY31170A1 (es) 2009-01-30
KR101525268B1 (ko) 2015-06-02
CR11231A (es) 2012-05-16
IL202729A0 (en) 2010-06-30
MY149316A (en) 2013-08-30
AU2008266746B2 (en) 2012-03-15
JP5281081B2 (ja) 2013-09-04
CN101874031A (zh) 2010-10-27
IL202729A (en) 2013-10-31
CO6261382A2 (es) 2011-03-22
TW200918542A (en) 2009-05-01
JP2010530431A (ja) 2010-09-09
CA2692099A1 (fr) 2008-12-24
US7829556B2 (en) 2010-11-09
WO2008156866A1 (fr) 2008-12-24
AU2008266746A1 (en) 2008-12-24
NZ581989A (en) 2012-06-29
CA2692099C (fr) 2016-08-09
ZA200908882B (en) 2010-08-25
US20090012080A1 (en) 2009-01-08
PE20090423A1 (es) 2009-04-18
KR20100038093A (ko) 2010-04-12
CL2008001821A1 (es) 2009-03-13
US8247565B2 (en) 2012-08-21
EP2167510B1 (fr) 2015-02-25
UA104127C2 (en) 2014-01-10

Similar Documents

Publication Publication Date Title
MA31568B1 (fr) Composes d'imidazothiazole modulant les sirtuines
MA31506B1 (fr) Composes modulant les sirtuines
MA32909B1 (fr) Composes thiazolopyridines de modulation des sirtuines
SG196775A1 (en) Chromenone analogs as sirtuin modulators
WO2009134973A8 (fr) Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
WO2006094210A3 (fr) Modulateurs de sirtuine de tetrahydroquinoxalinone
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
WO2007019344A8 (fr) Dérivés d'imidazo [2,1-b] thiayole en tant que modulateurs de sirtuine
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
WO2006094237A3 (fr) Modulateurs de la sirtuine a base d'acridine et de quineoline
WO2006094246A3 (fr) Modulateurs de sirtuine a base de n-arylmethyl benzamide
MA37450A1 (fr) Inhibiteurs d'indazole du trajet de signal de wnt et leurs utilisations thérapeutiques
TW200612926A (en) Compounds and compositions as ppar modulators
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2009061453A8 (fr) Thiazolopyridines solubilisées
WO2006084176A3 (fr) Composes et compositions utilises comme modulateurs de ppar
WO2007127474A3 (fr) Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2007022225A3 (fr) Composes nitres cycliques, compositions pharmaceutiques contenant ces composes et leurs applications
CA2631713A1 (fr) Modulateurs de kinases de type cdc2 (clks) et leurs procedes d'utilisation
IN2012DN03799A (fr)
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
WO2007056366A3 (fr) Composes et compositions utilises en tant que modulateurs des ppar
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA35875B1 (fr) Dérivés d'aza-adamantane et leurs utilisations